Response to fec chemotherapy and oncolytic hsv‐1 is associated with macrophage polarization and increased expression of s100a8/a9 in triple negative breast cancer

Abstract

The era of immunotherapy has seen an insurgence of novel therapies driving oncologic research and the clinical management of the disease. We have previously reported that a combination of chemotherapy (FEC) and oncolytic virotherapy (oHSV‐1) can be used to sensitize otherwise non‐responsive tumors to immune checkpoint blockade and that tumor‐infiltrating B cells are required for the efficacy of our therapeutic regimen in a murine model of triple‐negative breast cancer. In the studies herein, we have performed gene expression profiling using microarray analyses and have investigated the differential gene expression between tumors treated with FEC + oHSV‐1 versus untreated tumors. In this work, we uncovered a therapeutically driven switch of the myeloid phenotype and a gene signature driving increased tumor cell killing.